Comment on "Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis".

S Dhanya Dedeepya, Vaishali Goel, Nivedita Nikhil Desai

Abstract readLetter

In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

S Dhanya DedeepyaCenter for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India. dhanyadedeepya@gmail.com.ORCID http://orcid.org/0009-0001-0059-1387

Vaishali GoelFaculty of Pharmaceutical Sciences, Graphic Era Hill University, Dehradun, India.ORCID http://orcid.org/0009-0001-8623-7919

Nivedita Nikhil DesaiDr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-Be-University), Pimpri, Pune, Maharashtra, 411018, India.ORCID http://orcid.org/0009-0004-6016-1241

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary appraises Pieniążek et al.'s study on hematologic prognostic markers in sacituzumab govitecan-treated mTNBC, emphasizing residual confounding, absent Trop-2 data, limited modeling flexibility, and incomplete handling of missingness. Methodological refinement and integration of biological, longitudinal, and clinical variables are proposed to enhance prognostic accuracy and translational applicability.

Indexed as

Antibodies, Monoclonal, HumanizedBiomarkers, TumorCamptothecinHemoglobinsLymphocytesNeutrophilsTriple Negative Breast NeoplasmsFemaleHumansImmunoconjugatesPrognosisAntibodies, Monoclonal, HumanizedBiomarkers, TumorCamptothecinHemoglobinsImmunoconjugatessacituzumab govitecanHemoglobinNeutrophil-to-lymphocyte ratioPrognostic biomarkersSacituzumab govitecanTriple-negative breast cancer

Identifiers

PMID41348236

DOI10.1002/sim.9315

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.